Work

Assessment of normal plasma cell biomarkers after arlocabtagene autoleucel (arlo-cel) treatment in patients with ≥3L relapsed refractory multiple myeloma (MM).

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.7530

Authors: Kristina Jordahl, Wei-Ming Kao, Naomey Sarkis, Sandy Wong, Ethan G. Thompson, Shari Kaiser, Safiyyah Ziyad

Institution: Bristol-Myers Squibb (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410809748

Cites:

Cited by: 1

Related to: 10